XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...

Febuxostat 40 mg daily appears to be as efficacious as allopurinol in lowering serum uric acid levels. [38] Both febuxostat 40 and 80 mg can be given to patients with mild-to-moderate renal impair ...

An alternative XOI, Febuxostat, launched in the US in 2009 with the hope of treating allopurinol intolerant patients, however while Febuxostat achieved peak sales of approximately US$450 million2 ...

Attacks may be polyarticular and can intensify quickly. Colchicine in combination with probenecid or allopurinol is frequently used to treat gouty flares. [22] For acute attacks refractory to or ...

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. The company is actively involved in creating ...

Objective To assess the risk of hypersensitivity reactions (HSRs) with allopurinol and febuxostat in a population-based study. Methods We used the 5% Medicare beneficiary sample (≥65 years) from 2006 ...